Journal of Cardiovascular Development and Disease,
Год журнала:
2023,
Номер
10(6), С. 244 - 244
Опубликована: Май 31, 2023
Surgical
mortality
risk
scores,
even
if
not
properly
designed
and
rarely
tested
in
the
transcatheter
aortic
valve
implantation
(TAVI)
setting,
still
guide
heart
team
managing
significant
stenosis.After
splitting
1763
consecutive
patients
retrospectively
based
on
their
thresholds,
composite
endpoint
early
safety
(ES)
was
adjudicated
according
to
Valve
Academic
Research
Consortium
(VARC)-2
-3
consensus
documents.ES
incidence
higher
VARC-2
rather
than
VARC-3
defined.
Despite
only
showing
ES
had
significantly
lower
absolute
values
of
all
three
main
these
last
failed
foresee
both
intermediate-risk
patients.
The
receiver
operating
characteristic
analysis
also
showed
a
correlation,
but
with
poor
diagnostic
accuracy,
among
scores
ES;
moreover,
absence
low-osmolar
contrast
media
administration
were
identified
as
independent
predictors
1-year
ES,
respectively.
Finally,
single
complication
included
definition
could
affect
mortality.Currently,
most
used
do
have
adequate
accuracy
predicting
after
TAVI.
VARC-2,
instead
VARC-3,
is
an
predictor
mortality.
BMC Cardiovascular Disorders,
Год журнала:
2023,
Номер
23(1)
Опубликована: Июль 31, 2023
The
postoperative
outcomes
of
transcatheter
aortic
valve
replacement
(TAVR)
with
the
new
generation
self-expanding
valves
(SEV)
and
balloon-expandable
(BEV)
remain
uncertain.
Circulation Cardiovascular Interventions,
Год журнала:
2023,
Номер
16(1)
Опубликована: Янв. 1, 2023
Background:
In
recent
years,
transcatheter
aortic
valve
replacement
(TAVR)
techniques
and
technology
have
continuously
improved.
Data
regarding
the
impact
of
these
advancements
on
outcomes
in
large
real-world
settings
are
still
limited.
The
aim
this
study
was
to
investigate
temporal
trends
assess
contemporary
after
TAVR
with
Evolut
PRO/PRO+
supra-annular
self-expanding
valves.
Methods:
This
included
patients
enrolled
multicenter
NEOPRO
(A
Multicenter
Comparison
Acurate
NEO
Versus
PRO
Transcatheter
Heart
Valves)
NEOPRO-2
ACURATE
NEO2
Valves
2)
registries
who
underwent
transfemoral
PRO/PRO+.
Procedural
dates
(August
2017
through
November
2021)
were
stratified
quartiles
(Q)
used
outcomes.
Predischarge,
30-day
Valve
Academic
Research
Consortium-3
defined,
1-year
evaluated.
Results:
total,
1616
from
28
centers
included.
Over
time,
had
lower
Society
Thoracic
Surgeon-Predicted
Risk
Mortality
score
(Q1–4,
4.1%
[2.8–6.3%],
3.7%
[2.6–5.3%],
3.3%
[2.4–4.9%],
2.9%
[2.2–4.3%];
P
<0.001)
more
moderate
or
heavy
calcification
80%,
82%,
88%;
=0.038).
Overall
technical
success
94.1%,
all-cause
mortality
2.4%
10%,
respectively.
Throughout
period,
procedures
associated
higher
rates
device
81.2%,
82.2%,
82.0%,
88.0%;
Cochran-Armitage
=0.023)
early
safety
66.8%,
67.5%,
74.0%,
77.6%;
<0.001),
fewer
permanent
pacemaker
implantations
(Q1–4:
15.3%,
20.0%,
12.1%,
11.6%;
residual
mild
greater
paravalvular
leaks
50.4%,
42.1%,
36.5%,
35.8%;
<0.001).
Conclusions:
is
safe
effective.
Despite
treatment
heavier
calcified
anatomies,
procedural
improving
over
time
less
need
for
implantation
significant
leaks.
Frontiers in Cardiovascular Medicine,
Год журнала:
2024,
Номер
11
Опубликована: Апрель 8, 2024
Transcatheter
aortic
valve
replacement
(TAVR)
has
increasingly
become
a
safe,
feasible,
and
widely
accepted
alternative
surgical
treatment
for
patients
with
severe
symptomatic
stenosis.
However,
the
incidence
of
conduction
abnormalities
associated
TAVR,
including
left
bundle
branch
block
(LBBB)
high-degree
atrioventricular
(HAVB),
remains
high
is
often
correlated
risk
factors
such
as
severity
valvular
calcification,
preexisting
conditions
in
patients,
procedural
factors.
The
existing
research
results
on
impact
post-TAVR
permanent
pacemaker
(PPM)
requirements
prognosis,
all-cause
mortality
rehospitalization,
remain
contradictory,
varied
management
strategies
system
diseases
across
different
institutions.
This
review
integrates
latest
field,
offering
comprehensive
discussion
mechanisms,
factors,
consequences,
abnormalities.
study
provides
insights
into
optimizing
patient
prognosis
explores
potential
novel
strategies,
pacing,
to
minimize
adverse
clinical
outcomes.
EuroIntervention,
Год журнала:
2023,
Номер
19(2), С. e176 - e187
Опубликована: Июнь 1, 2023
Reducing
rates
of
permanent
pacemaker
implantation
(PPI)
after
transcatheter
aortic
valve
(TAVI)
is
important
for
achieving
the
best
procedural
outcomes.
The
cusp
overlap
technique
(COT)
implements
steps
including
an
angulation
right
and
left
coronary
to
mitigate
this
complication.
Journal of Clinical Medicine,
Год журнала:
2023,
Номер
12(1), С. 338 - 338
Опубликована: Янв. 1, 2023
Transcatheter
aortic
valve
implantation
(TAVI)
has
risen
over
the
past
20
years
as
a
safe
and
effective
alternative
to
surgical
replacement
for
treatment
of
severe
stenosis,
is
now
well-established
recommended
option
in
suitable
patients
irrespective
predicted
risk
mortality
after
surgery.
Studies
numerous
devices,
either
newly
developed
or
reiterations
previous
prostheses,
have
been
accruing.
We
hereby
review
TAVI
with
focus
on
commercially
available
options,
aim
present
guide
prosthesis
tailoring
according
patient-related
anatomical
clinical
factors
that
may
favor
particular
designs.
Catheterization and Cardiovascular Interventions,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 24, 2025
ABSTRACT
Transfemoral
transcatheter
aortic
valve
Replacement
(TAVR)
has
become
the
standard
therapy
for
patients
with
severe
stenosis
in
over
75
years
old
Europe
or
65
United
States,
regardless
of
surgical
risk.
Furthermore,
iterations
existing
valves
(TAVs),
as
well
devices
novel
concepts,
have
provided
substantial
improvements
respect
to
limitations
previous‐generation
devices.
Hence,
treatment
a
broader
spectrum
feasible,
and
sophisticated
selection
appropriate
TAV
tailored
patients'
anatomy
comorbidities
is
now
possible.
Anatomy,
patient
characteristics,
operator
experience
must
all
inform
proper
device
selection.
This
review
describes
features
performance
current
generation
TAVs
aim
providing
practical
approach
clinicians
when
selecting
specific
patient.
